- Lantern Pharmaโs AI-driven RADR(R) platform integrates over 200 billion oncology-specific data points and underpins every stage of its precision oncology pipeline.
- The company has three lead drug candidates in clinical development, targeting major oncology markets including NSCLC, TNBC, and NHL.
- Starlight Therapeutics extends Lanternโs footprint into brain and CNS cancers, including pediatric indications supported by orphan and rare disease designations.
- Lantern has received multiple FDA designations including Fast Track, Orphan Drug, and Rare Pediatric Disease status across its portfolio, enhancing regulatory pathways.
- With approximately $19.7 million in cash and equivalents, the company is funded through at least mid-2026 to support pipeline advancement and platform development.
Lantern Pharma (NASDAQ:ย LTRN)ย is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development. Through its proprietary platform, RADR(R) (Response Algorithm for Drug Positioning & Rescue), Lantern is advancing a pipeline of precision cancer therapies. The company has gained 11 FDA Designations for its portfolio of drug candidates including: Fast Track, Orphan and Pediatric Rare Disease. The companyโs data-driven approach enables rapid identification of promising drug candidates and the design of targeted clinical trials for specific patient subpopulations and cancer types.
Lanternโs vision is to transform cancer treatment by integrating large-scale genomics, AI-based biomarker discovery, and preclinical modeling to accelerate the development of oncology drugs. The companyโs pipeline includes three lead small molecule candidates and an antibody-drug conjugate (โADCโ)โฆ
NOTE TO INVESTORS:ย The latest news and updates relating to LTRN are available in the companyโs newsroom atย https://ibn.fm/LTRN
About BioMedWire
BioMedWireย (โBMWโ) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within theย Dynamic Brand Portfolioย @ย IBNย that delivers:ย (1) access to a vast network of wire solutions viaย InvestorWireย to efficiently and effectively reach a myriad of target markets, demographics and diverse industries;ย (2) article andย editorial syndication to 5,000+ outlets;ย (3) enhancedย press release enhancementย to ensure maximum impact;ย (4)ย social media distributionย via IBN to millions of social media followers;ย and (5) a full array of tailoredย corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in todayโs market, BMW brings its clients unparalleled recognition and brand awareness.
BMW is where breaking news, insightful content and actionable information converge.
To receive SMS alerts from BioMedWire, โBiotechโ to 888-902-4192 (U.S. Mobile Phones Only)
For more information, please visitย https://www.BioMedWire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:ย https://www.BioMedWire.com/Disclaimer
BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is powered byย IBN
